

Indiegene SoLi[®]

One Report | Multi-Dimensional Insights

Recommended

Advanced and metastatic cancers where multi-layered profiling enables accurate detection of actionable mutations and resistance pathways.



The Indiegene SoLiQ Advantage

COMPREHENSIVE COVERAGE OF 1212 GENES.

A Unified 1212-Gene Genomic Profiling Solution integrating Tissue, Liquid, and Germline Analysis for comprehensive precision oncology insights.



Reducing Blind Spot - Tumor Heterogeneity Captured

Solid and liquid biopsies together reveal spatially distinct mutations that may be missed in single-site sampling.



Baseline - to - Progression

Creates an integrated tissue and ctDNA molecular baseline that serves as a reference for monitoring disease evolution, therapeutic efficacy, dynamic clonal shifts, and the emergence of resistance over time for escalation and de-escalations and treatment changes for better outcome.



Confirmed - True Somatic

With matched Germline DNA, Indiegene SoLiQ differentiates true somatic mutations from inherited variants and clonal artifacts, significantly reducing false positives.




Filtered Out - Clonal Hematopoiesis

Indiegene SoLiQ distinguishes blood-derived Clonal Hematopoiesis (CH) variants from true tumor alterations using matched normal comparison, minimizing CH-related false positives and ensuring detection of clinically relevant tumor-derived variants.

The final clinical report consolidates insights across **Tissue**, **Blood**, and **Germline**, delivering deeper clarity for treatment selection, resistance analysis, and longitudinal planning.

Where traditional **CGP panels** rely on a single sample and risk false positives or missed mutations.



Assay Specification and Performance Overview



Gene Number

1212 Genes
(Tissue-Liquid-
Germline)



Sample Type

FFPE Tissue block ideally not more than 5 months old,
Fresh Frozen Tissue, with > 20% Tumor content.
2x10 ml Blood in Streck Tubes



Specificity and Sensitivity

99.99%



Turn Around Time

5 working days



Sequencing Chemistry

Hybrid Capture, End to End Sequencing of all the
Exons of a given Gene



Mean Sequencing Depth

2000X for tissue, 400X for
Germline blood and
15,000X for Liquid Biopsy

Revolutionising Care, Personalising Hope Globally

With Precision Oncology, we're not just treating cancer.
We're redefining what's possible in Cancer care.

Together, **We Beat** Cancer



● India ● Nepal ● Philippines ● UAE



For any further information on 4baseCare Solutions and Services, please contact:

 4basecare.com

 +91 636-684-3415

 info@4basecare.com

 3rd floor, Summit B, Brigade Metropolis, Garudachar Palya, Bengaluru, Karnataka 560048